Newsroom

Sorted by: Latest

-

Intero Real Estate Professionals Named in the 2026 RealTrends Verified City Rankings

CUPERTINO, Calif.--(BUSINESS WIRE)--Intero Real Estate Services, a wholly owned subsidiary of HomeServices of America, Inc., is pleased to announce 340 individual agents and teams were recognized in the 2026 RealTrends Verified City Rankings.Representing Team Intero are 297 individual agents, 37 small teams, 3 medium teams (The Nicoli Group, Elizabeth Fry Team, The Keith Walker Team), and 3 large teams (Tse Group, Troyer & Cabot Group, Vong Group).“These city-specific rankings further showca...
-

Riassunto: teamLab Biovortex Kyoto accoglie oltre 1 milione di visitatori nei primi 9 mesi dall'apertura

KYOTO, Giappone--(BUSINESS WIRE)--teamLab Biovortex Kyoto ha accolto più di 1 milione di visitatori al 6 luglio 2026, 9 mesi dopo la cerimonia di apertura ufficiale. (*1) I visitatori sono giunti da oltre 150 Paesi e regioni, rappresentando circa il 42% del totale delle presenze. Molti di questi visitatori internazionali arrivano da Paesi e regioni lontane, tra cui Stati Uniti, Australia, Canada, Regno Unito e Germania. Circa il 30% di questi visitatori internazionali acquista i propri bigliett...
-

teamLab Biovortex Kyoto accueille plus d’un million de visiteurs en l’espace de 9 mois après son ouverture

KYOTO, Japon--(BUSINESS WIRE)--teamLab Biovortex Kyoto a accueilli plus d’un million de visiteurs au 6 juillet 2026, soit 9 mois après son inauguration. (*1) Ces visiteurs provenaient de plus de 150 pays et régions. Les visiteurs internationaux représentent environ 42 % du total. Bon nombre de ces visiteurs internationaux viennent de pays et de régions lointaines, notamment des États-Unis, d’Australie, du Canada, du Royaume-Uni et d’Allemagne. Environ 30 % de ces visiteurs internationaux achète...
-

teamLab Biovortex Kyoto begrüßt innerhalb von 9 Monaten nach der Eröffnung mehr als 1 Million Besucher

KYOTO, Japan--(BUSINESS WIRE)--teamLab Biovortex Kyoto hat bis zum 6. Juli 2026, also 9 Monate nach der offiziellen Eröffnung mehr als 1 Million Besucher begrüßt. (*1) Die Besucher kamen aus mehr als 150 Ländern und Regionen. Der Anteil der internationalen Besucher beträgt etwa 42 % der Gesamtbesucherzahl. Viele dieser internationalen Besucher reisen aus weit entfernten Ländern und Regionen an, darunter die Vereinigten Staaten, Australien, Kanada, das Vereinigte Königreich und Deutschland. Etwa...
-

U.S. Plastics Pact Releases Updated Design Handbooks to Advance Circular Economy for Plastics

WALPOLE, N.H.--(BUSINESS WIRE)--The U.S. Plastics Pact today released updated design handbooks, providing comprehensive guidance for designing plastic packaging that can be successfully reused, recycled, or composted within existing and emerging U.S. infrastructure.The strengthened Recyclable, Compostable, and Reusable Packaging Design Handbooks translate the latest certification requirements, labeling rules, and implementation learnings into actionable guidance for packaging designers, engineer...
-

Inside ESSENCE Girls United and Kensington Grey’s Second Annual Creator Mixer during the 2026 ESSENCE Festival of Culture®

NEW ORLEANS--(BUSINESS WIRE)--During ESSENCE Festival of Culture® weekend, ESSENCE Girls United and Kensington Grey brought creators, storytellers, and culture shapers together at Common House New Orleans for their second annual creator mixer, a gathering designed to turn digital community into real-life connection. Held on Saturday, July 4, the event convened a dynamic mix of rising and established creators, media, tastemakers, and industry voices for an afternoon rooted in collaboration, visi...
-

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patient...
-

Deadline Soon: Phreesia Inc. (PHR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 13, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Phreesia Inc. (“Phreesia” or the “Company”) (NYSE: PHR) common stock between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON PHREESIA INC. (PHR), CLICK HERE PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT...
-

Protolabs Named to TIME’s 2026 List of America’s Best Companies

MINNEAPOLIS--(BUSINESS WIRE)--Protolabs (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced it has been named to TIME's list of America’s Best Companies of 2026. The recognition reflects Protolabs' continued commitment to fostering an exceptional workplace while helping customers accelerate innovation and bring products to market faster through digital manufacturing. This recognition comes as manufacturers increasingly adopt digital technologies and AI...
-

Charles Schwab Investment Management, Inc. UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions...